/ARDT

Ardent Health Inc

ARDT

$10.98USD↑+0.73%+0.08 today

MARKET CAP

1.5B

P/E (TTM)

11.6x

FWD P/E

—

DAY RANGE

$11 – $11

52W RANGE

$8

$15

AI Summary

Stalk

StalkMedium

ARDT broke above its June consolidation but has since drifted sideways near its short-term EMAs without decisive follow-through. The 9, 20, and 50 EMAs are flat to slightly rising, holding price support, while RSI and Options Score remain neutral, signaling no exhaustion. Medium-term bias stays bullish within a Stage 3 regime, but timing is unfavorable until renewed momentum emerges. A pullback to the 10.8–10.9 EMA zone offers a more defined engagement area. The long-term 200-day SMA is still declining, underscoring structural risk.

↑Operating cash flow surged 68% YoY to $197M in Q2 2026.
↑Repurchased $13M of stock in Q2 with $34M authorization remaining.
↓Q2 surgeries declined 2.9%, highlighting demand volatility.

Full analysis →

Buying

4

institutions

Selling

5

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	2.18 M	21.42 M	+418.13 K	+42.3%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	1.45 M	14.25 M	+505.46 K	+76.6%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	242.33 K	2.41 M	+73.72 K	+72.8%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUYNEW	119.08 K	1.17 M	+119.08 K	+0.0%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	113.50 K	1.12 M	+-55.43 K	-22.8%	0.00%
MM Millennium Management LLC Q2 2026	SELL	48.01 K	472.39 K	+-18.34 K	-16.8%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	23.42 K	230.49 K	+-20.45 K	-38.6%	0.00%
MC Moore Capital Management, LP Q2 2026	SELL	0.00	0.00	+-166.41 K	-100.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-10.90 K	-100.0%	0.00%